KLRK1 and neoplasm: CYAD-101, a NKG2D-based, non-gene-edited allogeneic CAR-T cell line, has shown the ability to sustain CAR-directed anti-tumor activity without inducing graft-versus-host disease (GvHD) [31, 32].